All articles tagged with #glp 1 agonists
A new study in Nature demonstrates that semaglutide, a GLP-1 receptor agonist, slows aging and extends lifespan in female mice. While these drugs are approved for diabetes and obesity, emerging evidence suggests they offer broader therapeutic benefits beyond weight loss and glucose control, though the specific mechanisms remain unclear.
A new review in Biological Psychiatry suggests that GLP-1 receptor agonists, such as semaglutide, may help reduce heavy drinking days and overall alcohol intake for some individuals. However, the evidence is inconsistent regarding whether these drugs effectively reduce alcohol cravings. While clinical trials show promising results for reducing consumption, particularly in people with obesity, the data does not yet confirm a direct link to reduced cravings or establish the drugs as a standard treatment for alcohol use disorder.
The official renaming of polycystic ovary syndrome (PCOS) to polyendocrine metabolic ovarian syndrome (PMOS) in May 2026 aims to better reflect the condition's systemic nature. While the diagnostic criteria remain unchanged, the new name acknowledges that ovarian cysts are not a requirement for diagnosis. This shift highlights significant diagnostic delays, with many patients waiting years for confirmation, and underscores the need for treatments addressing insulin resistance and metabolic issues rather than just symptom masking.
Eli Lilly’s experimental triple-agonist drug, retatrutide, has demonstrated unprecedented weight loss in late-stage clinical trials. In a phase 3 study for patients with Type 2 diabetes, participants lost up to 23% of their body weight, while those with obesity but no diabetes lost up to 25%. The drug targets three hormones, including glucagon, to enhance metabolic effects beyond existing GLP-1 therapies. Lilly plans to file for FDA approval early next year, though unapproved versions are already circulating.
Microdosing GLP-1 receptor agonists like semaglutide and tirzepatide at doses significantly lower than standard prescriptions is gaining traction among clinicians treating perimenopausal women. This approach aims to address metabolic shifts caused by declining estrogen, which naturally reduces the body's own GLP-1 signaling. While low doses may improve insulin sensitivity and reduce gastrointestinal side effects, the practice remains off-label with limited rigorous scientific support. Experts emphasize that while metabolic benefits may precede weight loss, the lack of standardized guidelines and potential risks, such as muscle loss, necessitate careful, individualized medical supervision.
Research from Virginia Tech suggests that weight loss drugs, specifically GLP-1 agonists, delay alcohol absorption, reducing the immediate effects and potentially helping people cut back on drinking, which could be beneficial for alcohol use disorder treatment.
Research warns of dangers associated with starting and stopping weight loss shots like Semaglutide, including serious side effects, potential for weight regain, and muscle loss. Medical professionals emphasize the importance of understanding risks, addressing underlying health issues, and adopting sustainable lifestyle changes to maintain weight loss long-term. A special offer for a comprehensive health assessment is available at Health Utah.
Research warns of dangers from starting and stopping weight loss shots like Semaglutide, including serious side effects and weight regain. Medical professionals highlight risks such as severe pain, organ issues, and potential death, emphasizing the importance of informed decision-making and comprehensive health strategies for sustainable weight management.
Research warns of dangers from starting and stopping weight loss shots like Semaglutide, including serious side effects and weight regain. Medical professionals highlight risks such as severe pain, organ issues, and potential death, emphasizing the importance of informed decisions and comprehensive health strategies for sustainable weight management. Dr. Roberts advocates for addressing underlying health issues and adopting personalized, holistic approaches to maintain weight loss without relying solely on medication.
A Japanese study suggests that emotional eating may reduce the effectiveness of weight loss drugs like Ozempic, as emotional eaters tend to revert to unhealthy habits over time, potentially due to underlying psychological issues. External eaters, however, continue to improve, indicating that behavioral and psychological support might enhance treatment outcomes. Further research is needed to confirm these findings and improve personalized treatment strategies.
A study suggests that GLP-1 drugs like Ozempic are more effective for individuals whose overeating is triggered by external cues rather than emotional reasons, highlighting the importance of behavioral assessments in treatment planning.
A large study shows that weight loss drugs like semaglutide and tirzepatide can significantly reduce the risk of hospitalization and early death in heart failure patients with obesity and type 2 diabetes, potentially offering a new treatment avenue for these patients.
The term 'Ozempic vulva' refers to sagging skin and other changes in the vulvar area reported by women using GLP-1 agonists like Ozempic for weight loss, likely due to rapid fat loss and muscle weakening. While some opt for non-invasive treatments like moisturizers or pelvic exercises, others consider procedures such as labia puffing or labiaplasty. More scientific research is needed to understand these effects fully.
Recent studies suggest that GLP-1 agonist drugs like Ozempic and Wegovy, used for weight loss and diabetes management, may carry a small risk of serious eye conditions such as NAION and diabetic retinopathy, but the overall risk appears modest and requires further research. Patients with risk factors should consult their doctors and undergo regular eye exams to monitor eye health while on these medications.
A recent study suggests that GLP-1 agonists may offer better protection against dementia in people with type 2 diabetes compared to metformin, with findings indicating a significantly lower risk of developing dementia and Alzheimer’s disease among GLP-1 users. The research highlights the potential neuroprotective benefits of GLP-1 medications, which could influence future treatment strategies for diabetes and cognitive decline.